Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

Bibliography

• BAGSHAWE KD: antibody directed enzymes revive anticancer prodrugs concept. Br.j Cancer (1987) 56:531–532.
   PubMed Web of Science ®Google Scholar
• ••First description of the principleof ADEPT.
   Google Scholar
• BAGSHAWE KD, SPRINGER CJ,SEARLE F et al.: A cytotoxic agent can begenerated selectively at cancer sites. Br. Cancer (1988) 58:700–703.
   PubMed Web of Science ®Google Scholar
• ••First proof of principle of ADEPT.
   Google Scholar
• PRESSMAN D, KORNGOLD L: The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer (1953) 6:619–623.
   PubMed Web of Science ®Google Scholar
• MACH JP, CARREL S, MERENDA C, SORDAT B, CEROTTINI JC: In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature (1974) 248:704–706.
   PubMed Web of Science ®Google Scholar
• GOLDENBERG DM, DELAND F, KIM E et al.: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl. J. Med. (1978) 298:1384–1386.
   PubMed Web of Science ®Google Scholar
• BEGENT RH, SEARLE F, STANWAY G et al.: Radioimmunolocalization of tumours by external scintigraphy after administration of 1311 antibody to human chorionic gonadotrophin: preliminary communication. I R. Soc. Med. (1980) 73:624–630.
   PubMed Web of Science ®Google Scholar
• GOLD P, FREEDMAN SO: Tests for carcinoembryonic antigen. Role in diagnosis and management of cancer. JAMA (1975) 234:190–192.
   Google Scholar
• PEDLEY RB, BODEN JA, BODEN RW,GREEN A, BOXER GM,BAGSHAWE KD: The effect of serum CEA on the distribution and clearance of anti- CEA antibody in a pancreatic tumor xenograft model. Br. J. Cancer (1989) 60:549–554.
   PubMed Web of Science ®Google Scholar
• KOHLER G, MILSTEIN C: Continuouscultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495–497.
   PubMed Web of Science ®Google Scholar
• •First description of monoclonal antibody production.
   Google Scholar
• EDWARDS PA: Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonalantibodies. Br. J. Cancer (1985) 51:149-160.II. RETTA BME, BURKE PJ, PHOTIOU A, MELTON RG, ENOAMOOQUAYE E: Antibody-directed enzyme prodrug therapy (ADEPT): Evidence for a bystander effect in vitro. Int.j Oncol. (1996) 9:567–570.
   Google Scholar
• CHENG TL, VVEI SL, CHEN BM et al:Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br. Cancer (1999) 79:1378–1385.
   Google Scholar
• PEDLEY RB, BODEN JA, BODEN R, DALE R, BEGENT RHJ: Comparative radioimmunotherapy using intact or F(A02 fragments of 1-131 anti-CEA antibody in a colonic xenograft model. Br. J. Cancer (1993) 68:69–73.
   PubMed Web of Science ®Google Scholar
• MELTON RG, SEARLE F,SHERWOOD RF, BAGSHAWE KD, BODEN JA: The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. Li vivo localising and clearance properties in a choriocarcinoma model. Br. Cancer (1990) 61:420–424.
   Google Scholar
• HUSE, WD, SASTRY L, IVERSON SA et al.: Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science (1989) 246:1275–1281.
   PubMed Web of Science ®Google Scholar
• •First description of generation of phage libraries for antibody production.
   Google Scholar
• MCCAFFERTY J, GRIFFITHS AD,WINTER G, CHISWELL DJ: Phage antibodies: filamentous phage displaying antibody variable domains. Nature (1990) 348:552–554.
   PubMed Web of Science ®Google Scholar
• CHESTER KA, BEGENT RH, ROBSON L et al.: Phage libraries for generation of clinically useful antibodies. Lancet (1994) 343:455–456.
   PubMed Web of Science ®Google Scholar
• •Generation of single-chain antibodies for imaging and therapy.
   Google Scholar
• PEDLEY, RB, BODEN JA, BODEN, R et al.: The potential for enhanced tumor-localization by poly(ethylene glycol) modification of anti- CEA antibody. Br. Cancer (1994) 70:1126–1130.
   Google Scholar
• CALICETI P, VERONESE FM: Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv. Drug Deify. Rev. (2003) 55:1261–1277.
   PubMed Web of Science ®Google Scholar
• SMITH BJ, POPPLE WELL A, ATHWAL D et al: A. Prolonged M vivo residence times of antibody fragmentsassociated with albumin. Bioconjug. Chem. (2001) 12:750–756.
   Google Scholar
• DUNCAN R: Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs (1992) 3:175–210.
   PubMed Web of Science ®Google Scholar
• MAEDA H, SEYMOUR LW,MIYAMOTO Y: Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. (1992) 3:351–362.
   PubMed Web of Science ®Google Scholar
• SEYMOUR LW: Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev Ther: Drug Carrier Syst. (1992) 9:135–187.
   PubMed Web of Science ®Google Scholar
• SATCHI-FAINARO R, HAILU H, DAVIES JVV, SUMMERFORD C, DUNCAN R: PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug. Chem. (2003) 14:797–804.
   Google Scholar
• STUBDAL H, PERIN N, LEMMON M et al: A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res. (2003) 63:6900–6908.
   PubMed Web of Science ®Google Scholar
• WILDNER 0, BLAESE RIVI, CANDOTTI F: Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res. (1999) 59:5233–5238.
   PubMed Web of Science ®Google Scholar
• NICULESCU-DUVAZ I, SPOONER R, MARAIS R, SPRINGER CJ: Gene-directed enzyme prodrug therapy. Bioconjug. Chem. (1998) 9:4–22.
   PubMed Web of Science ®Google Scholar
• ••Good review of GDEPT.
   Google Scholar
• PHILPOTT, GW, BOWER RJ,PARKER CW: Selective iodination and cytotoxicity of tumor cells with an antibody-enzyme conjugate. Surgery (1973) 74:51–58.
   PubMed Web of Science ®Google Scholar
• •First use of antibody-enzyme conjugate.
   Google Scholar
• SHERWOOD RE MELTON RG, AL WAN SM, HUGHES P: Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Ear: Biochem. (1985) 148:447–453.
   Google Scholar
• CHABNER, BA, CHELLO PL, BERTINO JR: Antitumor activity of a folate-cleaving enzyme, carboxypeptidase Gl. Cancer Res. (1972) 32:2114–2119.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE KD, SHARMA SK, SPRINGER CJ et al.: Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites. Antibody Immunoconjug. Radiophann. (1991) 4:915–922.
   Google Scholar
• ALEXANDER RP, BEELEY NRA, ODRISCOLL M et al.: Cephalosporin nitrogen-mustard carbamate prodrugs for ADEPT. Tetrahedron Lett. (1991) 32:3269–3272.
   Web of Science ®Google Scholar
• VRUDHULA VM, SVENSSON HP, SENTER PD: Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-beta-lactamase conjugates.' Med. Chem. (1995) 38:1380–1385.
   Web of Science ®Google Scholar
• MEYER DL, JUN GHEIM LN, LAW KL et al.: Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res. (1993) 53:3956–3963.
   PubMed Web of Science ®Google Scholar
• RODRIGUES ML, CARTER P, WIRTH C, MULLINS S, LEE A, BLACKBURN BK: Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug. Chem. Biol (1995) 2:223–227.
   PubMed Web of Science ®Google Scholar
• HANESSIAN S, WANG JG: Design and synthesis of a cephalosporin carboplatinum prodrug activatable by a beta-lactamase. Can. J. Chem. Rev. Can. Chimie (1993) 71:896–906.
   Web of Science ®Google Scholar
• WALLACE PM, MACMASTER IF, SMITH VF, KERR DE, SENTER PD, COSAND WL: Intratumoral generation of 5-fluorouracil mediated by an antibody cytosine deaminase conjugate in combination with 5- fluorocytosine. Cancer Res. (1994) 54:2719–2723.
   PubMed Web of Science ®Google Scholar
• SENTER PD, SAULNIER MG, SCHREIBER GJ et al.: Anti-tumor effects of antibody alkaline-phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA (1988) 85:4842–4846.
   PubMed Web of Science ®Google Scholar
• •First proof of principle of ADEPT.
   Google Scholar
• SMITH GK, BANKS S,BLUMENKOPF TA et al.: Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase Al and novel in vivo stable prodrugs of methotrexate. Biol. Chem. (1997) 272:15804–15816.
   Google Scholar
• HOUBA PHI, LEENDERS RGG, BOVEN E, SCHEEREN JW, PINEDO HM, HAISMA HI: Characterization of novel anthracycline prodrugs activated by humanbeta-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem. Pharmacol (1996) 52:455–463.
   PubMed Web of Science ®Google Scholar
• BOSSLET K, CZECH J,HOFFMANN D: Tumor-selective prodrugactivation by fusion protein-mediated catalysis. Cancer Res. (1994) 54:2151–2159.
   PubMed Web of Science ®Google Scholar
• MICHAEL NP, CHESTER KA, MELTON RG et al: ha vitro and in vivo characterisation of a recombinant carboxypeptidase G(2)::anti-CEA scFy fusion protein. Immunotechnology (1996) 2:47–57.
   PubMedGoogle Scholar
• BHATIA J, SHARMA SK, CHESTER KA et al.: Catalytic activity of an in vivo tumor targeted anti- CEA scFv::carboxypeptidase G2 fusion protein. hat. J Cancer (2000) 85:571–577.
   PubMed Web of Science ®Google Scholar
• MEDZIHRADSZKY KF, SPENCER DI, SHARMA SK et al: Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Clycobiology (2004) 14:27–37.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, PEDLEY RB, IRWIN HL et al.: The effect of adept, as a single or combined therapy, in two colorectal xenografts. Br. Cancer (2003) 88:S37.
   Google Scholar
• SIEMERS NO, KERR DE, YARNOLD S et al: Construction, expression, and activities of L49-sFy-beta- lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. Bioconjug. Chem. (1997) 8:510–519.
   PubMed Web of Science ®Google Scholar
• MCDONAGH CE BEAM KS, WU GJ et al.: Improved yield and stability of L49-sFy-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering. Bioconjug. Chem. (2003) 14:860–869.
   Google Scholar
• DECKERT PM, RENNE C, COHEN LS et al: A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy. Br: J. Cancer (2003) 88:937–939.
   Google Scholar
• BOSSLET K, CZECH J, LORENZ P, SEDLACEK HH, SCHUERMANN M, SEEMANN G: Molecular and functional-characterization of a fusion protein suited for tumor specific prodrug activation. Br. Cancer (1992) 65:234–238.
   Google Scholar
• •Use of genetic antibody-enzyme fusion protein.
   Google Scholar
• BIELA BH, KHAWLI LA, HU PS, EPSTEIN AL: Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother. Radiopharm. (2003) 18:339–353.
   PubMed Web of Science ®Google Scholar
• GOSHORN SC, SVENSSON HP, KERR DE, SOMERVILLE JE, SENTER PD, FELL HP: Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase. Cancer Res. (1993) 53:2123–2127.
   PubMed Web of Science ®Google Scholar
• KERR DE, SCHREIBER GJ,VRUDHULA VM et al: Regressions and cures of melanoma xenografts following treatment with monoclonal-antibody beta-lactamase conjugates in combination with anticancer prodrugs. Cancer Res. (1995) 55:3558–3563.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BAGSHAWE KD, BURKE PJ, BODEN RW, ROGERS GT: Inactivation and clearance of an anti- CEA carboxypeptidase-G2 conjugate in blood after localization in a xenograft model. Br. J Cancer (1990) 61:659–662.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BAGSHAWE KD, SPRINGER CJ et al.: Antibody directed enzyme prodrug therapy (ADEPT) - a three phase system. Dis. Markers (1991) 9:225–231.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BAGSHAWE KD, BURKE PJ et al.: Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer (1994) 73:1114–1120.
   PubMed Web of Science ®Google Scholar
• SHARMA SK: Accelerated clearance systems. Adv. Drug Deify. Rev (1996) 22:315–324.
   Web of Science ®Google Scholar
• •Review of systems to reduce enzyme activity in blood.
   Google Scholar
• BAGSHAWE KD, SHARMA SK, SPRINGER CJ et al.: Antibody directed enzyme prodrug therapy (ADEPT) - clinical report. Dis. Markers (1991) 9:233–238.
   PubMed Web of Science ®Google Scholar
• ••First brief clinical report of ADEPT.
   Google Scholar
• BAGSHAWE KD, SHARMA SK, SPRINGER CJ, ANTONIW P: Antibody-directed enzyme prodrug therapy: a pilot scale clinical trial. Tumor Targeting (1995) 1:17–29.
   Google Scholar
• ••Detailed report of the first clinical trialof ADEPT.
   Google Scholar
• BAGSHAWE KD, BEGENT RHJ: First clinical experience with ADEPT. Adv. Drug Deliv. Rev (1996) 22:365–367.
   Web of Science ®Google Scholar
• ••Clinical trial of ADEPT.
   Google Scholar
• NAPIER MP, SHARMA SK,SPRINGER CJ et al: Antibody-directedenzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res. (2000) 6:765–772.
   PubMed Web of Science ®Google Scholar
• •Mechanistic study of a second clinical trial of ADEPT.
   Google Scholar
• KERR DE, GARRIGUES US, WALLACE PM, HELLSTROM KE, HELLSTROM I, SENTER PD: Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate. Bioconjug. Chem. (1993) 4:353–357.
   PubMed Web of Science ®Google Scholar
• CHENG TL, WU PY, WU MECHERN JW, ROFFLER SR: Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug. Chem. (1999) 10:520–528.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BAGSHAWE KD, MELTON RG, SHERWOOD RF: Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys. (1992) 21:109–120.
   PubMedGoogle Scholar
• LEDERMANN JA, BEGENT RH, BAGSHAWE KD: Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits. Br.Cancer (1988) 58:562–566.
   Google Scholar
• LEDERMANN JA, BEGENT RH, BAGSHAWE KD et al.: Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br. Cancer (1988) 58:654–657.
   Google Scholar
• BAGSHAWE KD, SHARMA SK: Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Transplant Proc. (1996) 28:3156–3158.
   PubMed Web of Science ®Google Scholar
• ABUCHOWSKI A, MCCOY JR, PALCZUK NC, VAN ES T, DAVIS FF: Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. Biol. Chem. (1977) 252:3582–3586.
   Web of Science ®Google Scholar
• SEHON AH: Suppression of IgE antibodyresponses with tolerogenic conjugates of allergens and haptens. Frog. Allergy (1982) 32:161–202.
   PubMedGoogle Scholar
• WILKINSON I, JACKSON CJ,LANG GM, HOLFORD-STREVENS V, SEHON AH: Tolerance induction in mice by conjugates of monoclonal immunoglobulins and monomethoxypolyethylene glycol. Transfer of tolerance by T cells and by T cell extracts. Immunol. (1987) 139:326–331.
   Google Scholar
• ••Use of polyethylene glycol toinduce tolerance.
   Google Scholar
• SPENCER DIR, ROBS ON L, PURDY D et al.: A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics (2002) 2:271–279.
   PubMed Web of Science ®Google Scholar
• •Mapping immunogenic epitopes of CPG2.
   Google Scholar
• MAYER A, SHARMA SK, TOLNER B et al.: Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br. Cancer (2004) 90:2402–2410.
   Google Scholar
• BAGSHAWE KD: The First Bagshawe Lecture. Towards generating cytotoxic agents at cancer sites. Br. Cancer (1989) 60:275–281.
   PubMed Web of Science ®Google Scholar
• ••Potential of ADEPT.
   Google Scholar
• SHABAT D, RADER C, LIST B, LERNER RA, BARBAS CF 3rd: Multiple event activation of a generic prodrug trigger by antibody catalysis. Proc. Nati Acad. Sci. USA (1999) 96:6925–6930.
   PubMed Web of Science ®Google Scholar
• ••Use of catalytic antibody forprodrug activation.
   Google Scholar
• RADER C, TURNER JM, HEINE A et al: A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. Biol. (2003) 332:889–899.
   Google Scholar
• ••Humanised catalytic antibody.
   Google Scholar
• SHAMIS M, LODE HN, SHABAT D: Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. J. Am. Chem. Soc. (2004) 126:1726–1731.
   PubMed Web of Science ®Google Scholar
• SINHA SC, LI LS, MILLER GP, DUTTA S, RADER C, LERNER RA: Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab. Proc. Nati Acad. Sci. USA (2004) 101:3095–3099.
   PubMed Web of Science ®Google Scholar
• KNOX RJ, FRIEDLOS F, BOLAND MP: The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev (1993) 12:195–212.
   PubMed Web of Science ®Google Scholar
• WILMAN DE: Prodrugs in cancer chemotherapy. Biochem. Soc. Trans. (1986) 14:375–382.
   PubMed Web of Science ®Google Scholar
• FREI E 3rd, TEICHER BA, HOLDEN SA,CATHCART KN, WANG YY: Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. (1988) 48:6417–6423.
   PubMed Web of Science ®Google Scholar
• •Dose correlation of alkylating agent in therapy.
   Google Scholar
• CROOP JM, RAYMOND M, HABER D et al.: The three mouse multidrug resistance (rndr) genes are expressed in a tissue-specificmanner in normal mouse tissues. Ma Cell. Biol. (1989) 9:1346–1350.
   Web of Science ®Google Scholar
• SPRINGER CJ, ANTONIW P, BAGSHAWE KD, SEARLE F,BISSET GM, JARMAN M: Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase-G2. J. Med. Chem. (1990) 33:677–681.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ, BAGSHAWE KD, SHARMA SK et al.: Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. Cancer. (1991) 27:1361–1366.
   PubMed Web of Science ®Google Scholar
• ANTONIW P, SPRINGER CJ,BAGSHAWE KD et al.: Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br. Cancer. (1990) 62:909–914.
   Google Scholar
• MARTIN J, STRIBBLING SM,POON GK et al.: Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a Phase I clinical trial. Cancer Chemothec Pharmacol (1997) 40:189–201.
   Google Scholar
• •Pharmacokinetics of prodrug and drug in the ADEPT clinical trial.
   Google Scholar
• SHARMA SK, BODEN JA,SPRINGER CJ, BURKE PJ, BAGSHAWE KD: Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts. Cell Biophys. (1994) 24–25:219–228.
   Google Scholar
• ECCLES SA, COURT W, BOX GA, DEAN CJ, MELTON RG,SPRINGER CJ: Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res. (1994) 54:5171–5177.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ, NICULESCUDUVAZ I, PEDLEY RB: Novel prodrugs of alkylating agents derived from 2-fluorobenzoic and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. j. Med. Chem. (1994) 37:2361–2370.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ, DOWELL R, BURKE PJ et al.: Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). .I. Med. Chem. (1995) 38:5051–5065.
   PubMed Web of Science ®Google Scholar
• •Chemistry of the prodrug ZD2767P.
   Google Scholar
• BLAKEY DC, BURKE PJ, DAVIES DH et al.: ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Cancer Res. 56: 3287–3292.
   Google Scholar
• •In vivo effects of generated drug ZD2767.
   Google Scholar
• MONKS NR, BLAKEY DC, CURTIN NJ,EAST SJ, HEUZE A, NEWELL DR: Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. Br. Cancer (2001) 85:764–771.
   Google Scholar
• •Mechanism of cell death by the ADEPT system.
   Google Scholar
• VRUDHULA VM, SENTER PD, FISCHER KJ, WALLACE PM: Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate.' Med. Chem. (1993) 36:919–923.
   Web of Science ®Google Scholar
• WALLACE PM, SENTER PD: Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Methods Find. Exp. Clin. Pharmacol (1994) 16:505–512.
   PubMed Web of Science ®Google Scholar
• CHENG TL, CHEN BM, CHAN LY, WU PY, CHERN JW, ROFFLER SR: Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immunol Immunother (1997) 44:305–315.
   PubMed Web of Science ®Google Scholar
• ANLEZARK GM, MELTON RG, SHERWOOD RF, COLES B,FRIEDLOS F, KNOX RJ: The bioactivation of 5-(aziridin-1-Y0-2,4-dinitrobenzamide (Cb1954).1. Purification and properties of a nitroreductase enzyme from Escherichia coil - a potential enzyme for antibody- directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol (1992) 44:2289–2295.
   Google Scholar
• ABOAGYE EO, ARTEMOV D,SENTER PD, BHUJWALLA ZM: Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Cancer Res. (1998) 58:4075–4078.
   PubMed Web of Science ®Google Scholar
• FLORENT JC, DONG X, GAUDEL G et al.: Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. Med. Chem. (1998) 41:3572–3581.
   Web of Science ®Google Scholar
• LEU YL, ROFFLER SR, CHERN JW: Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). .I. Med. Chem. (1999) 42:3623–3628.
   PubMed Web of Science ®Google Scholar
• WRASIDLO W, GAEDICKE G, GUY RK et al: A novel 2'-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. Bioconjug. Chem. (2002) 13:1093–1099.
   PubMed Web of Science ®Google Scholar
• •Preclinical study of a novel prodrug.
   Google Scholar
• SENTER PD, BEAM KS, MIXAN B, WAHL AF: Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjug. Chem. (2001) 12:1074–1080.
   PubMed Web of Science ®Google Scholar
• •Use of human enzymes in ADEPT.
   Google Scholar
• BIGNAMI GS, SENTER PD, GROTHAUS PG, FISCHER KJ, HUMPHREYS T, WALLACE PM: N-(4'-hydroxyphenylacetyl)palytoxin: a palytwdn prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res. (1992) 52:5759–5764.
   PubMed Web of Science ®Google Scholar
• BLAKEY DC, DAVIES DH, DOWELL RI et al.: Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Br. Cancer (1995) 72:1083–1088.
   Google Scholar
• SHABAT D, LODE HN, PERTL U et al..: In vivo activity in a catalytic antibody-prodrug system: antibody catalyzedetoposide prodrug activation for selective chemotherapy. Proc. Nati Acad. Sci. USA (2001) 98:7528–7533.
   PubMed Web of Science ®Google Scholar
• •Use of catalytic antibody in ADEPT.
   Google Scholar
• FRANCIS RJ, SHARMA SK, SPRINGER CJ et al.: A Phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. Cancer. (2002) 87:600–607.
   Google Scholar
• ••ADEPT clinical trial usingantibody-enzyme conjugates without the clearing antibody and the new prodrug ZD2767P.
   Google Scholar
• MAYER A, FRANCIS R, SHARMA SK et al.: A Phase I/II trial of antibody directed enzyme prodrug therapy (ADEPT) with MFECP1 and ZD2767P. Br. Cancer (2004) 91\(Suppl. 1):58.
   Google Scholar
• ••First report of an ADEPT clinical trialusing a recombinant glycosylated fusion protein and the ZD2767P prodrug.
   Google Scholar
• PEDLEY RB, SHARMA SK, BOXER GM et al.: Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. (1999) 59:3998–4003.
   PubMed Web of Science ®Google Scholar
• •First report of ADEPT combination therapy.
   Google Scholar